MovDisordV3, PascalFrancis, Corpus, bibRecord, 002394

Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease

Identifieur interne : 002394 ( PascalFrancis/Corpus ); précédent : 002393; suivant : 002395

Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease

Auteurs : Amy J. Bastian ; Valerie E. Kelly ; Joel S. Perlmutter ; Jonathan W. Mink

Source :

Movement disorders [ 0885-3185 ] ; 2003.

RBID : Pascal:04-0052798

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Lévodopa, Chimiothérapie, Pallidum, Exérèse, Unilatéral, Marche à pied, Mouvement corporel, Atteignabilité, Cinématique, Traitement associé, Pronostic, Adulte.

English descriptors

KwdEn :
- Adult, Body movement, Chemotherapy, Combined treatment, Exeresis, Kinematics, Levodopa, Pallidum, Parkinson disease, Prognosis, Reachability, Unilateral, Walking.

Abstract

We examined the effects of levodopa and unilateral pallidotomy on quantitative measures of walking and reaching in Parkinson's disease (PD). We also compared quantitative measures of movement with standard clinical rating scales. We used kinematic measures and the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale (subscale III) to evaluate the movement of 10 people with PD. Subjects were tested after withholding PD medications for at least 8 hours and again 30 to 45 minutes after taking the first morning dose of levodopa. They were studied in this manner before unilateral pallidotomy and then 3.5 to 10 months after surgery. The UPDRS motor subscale was performed in each state. Kinematic data were collected as subjects reached to a target and walked. The UPDRS motor subscale ratings were similar to those reported in the literature: pallidotomy improved the overall motor score and the contralateral bradykinesia + rigidity score, but not the gait + posture score. In contrast, kinematic measures demonstrated that levodopa and pallidotomy had different effects on walking and reaching speed. Both treatments improved walking speed, and the effect was additive. Levodopa improved reaching speed before pallidotomy but did not improve it as much after pallidotomy. Additionally, pallidotomy had inconsistent effects on reaching; some subjects were faster and others were slower. The subjects who initially reached more slowly improved after pallidotomy; the subjects who initially reached more normally (faster) worsened after pallidotomy. On the basis of our results, we speculate that basal ganglia output pathways that control walking and reaching may be distinct. such that bilateral projections to the pedunculopontine area influence walking, whereas ipsilateral thalamocortical projections influence reaching.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 18`
A06				`@2 9`
A08	`01`	`1`	`ENG`	`@1 Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease`
A11	`01`	`1`		`@1 BASTIAN (Amy J.)`
A11	`02`	`1`		`@1 KELLY (Valerie E.)`
A11	`03`	`1`		`@1 PERLMUTTER (Joel S.)`
A11	`04`	`1`		`@1 MINK (Jonathan W.)`
A14	`01`			`@1 Kennedy Krieger Institute @2 Baltimore, Maryland @3 USA @Z 1 aut.`
A14	`02`			`@1 Program in Physical Therapy, Washington University @2 St. Louis, Missouri @3 USA @Z 1 aut. @Z 2 aut.`
A14	`03`			`@1 Departments of Neurology, Radiology, and Anatomy & Neurobiology, Washington University @2 St. Louis, Missouri @3 USA @Z 3 aut.`
A14	`04`			`@1 Departments of Neurology (Child Neurology), Neurobiology & Anatomy, and Pediatrics, University of Rochester @2 Rochester, New York @3 USA @Z 4 aut.`
A14	`05`			`@1 Department of Neurology, Johns Hopkins @2 Baltimore, Maryland @3 USA`
A20				`@1 1008-1017`
A21				`@1 2003`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000113072050060`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 40 ref.`
A47	`01`	`1`		`@0 04-0052798`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 We examined the effects of levodopa and unilateral pallidotomy on quantitative measures of walking and reaching in Parkinson's disease (PD). We also compared quantitative measures of movement with standard clinical rating scales. We used kinematic measures and the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale (subscale III) to evaluate the movement of 10 people with PD. Subjects were tested after withholding PD medications for at least 8 hours and again 30 to 45 minutes after taking the first morning dose of levodopa. They were studied in this manner before unilateral pallidotomy and then 3.5 to 10 months after surgery. The UPDRS motor subscale was performed in each state. Kinematic data were collected as subjects reached to a target and walked. The UPDRS motor subscale ratings were similar to those reported in the literature: pallidotomy improved the overall motor score and the contralateral bradykinesia + rigidity score, but not the gait + posture score. In contrast, kinematic measures demonstrated that levodopa and pallidotomy had different effects on walking and reaching speed. Both treatments improved walking speed, and the effect was additive. Levodopa improved reaching speed before pallidotomy but did not improve it as much after pallidotomy. Additionally, pallidotomy had inconsistent effects on reaching; some subjects were faster and others were slower. The subjects who initially reached more slowly improved after pallidotomy; the subjects who initially reached more normally (faster) worsened after pallidotomy. On the basis of our results, we speculate that basal ganglia output pathways that control walking and reaching may be distinct. such that bilateral projections to the pedunculopontine area influence walking, whereas ipsilateral thalamocortical projections influence reaching.
C02	`01`	`X`		`@0 002B02B06`
C02	`02`	`X`		`@0 002B25J01`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`02`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`03`	`X`	`FRE`	`@0 Chimiothérapie @5 05`
C03	`03`	`X`	`ENG`	`@0 Chemotherapy @5 05`
C03	`03`	`X`	`SPA`	`@0 Quimioterapia @5 05`
C03	`04`	`X`	`FRE`	`@0 Pallidum @5 07`
C03	`04`	`X`	`ENG`	`@0 Pallidum @5 07`
C03	`04`	`X`	`SPA`	`@0 Pallidum @5 07`
C03	`05`	`X`	`FRE`	`@0 Exérèse @5 08`
C03	`05`	`X`	`ENG`	`@0 Exeresis @5 08`
C03	`05`	`X`	`SPA`	`@0 Exéresis @5 08`
C03	`06`	`X`	`FRE`	`@0 Unilatéral @5 09`
C03	`06`	`X`	`ENG`	`@0 Unilateral @5 09`
C03	`06`	`X`	`SPA`	`@0 Unilateral @5 09`
C03	`07`	`X`	`FRE`	`@0 Marche à pied @5 10`
C03	`07`	`X`	`ENG`	`@0 Walking @5 10`
C03	`07`	`X`	`SPA`	`@0 Caminata @5 10`
C03	`08`	`X`	`FRE`	`@0 Mouvement corporel @5 11`
C03	`08`	`X`	`ENG`	`@0 Body movement @5 11`
C03	`08`	`X`	`SPA`	`@0 Movimiento corporal @5 11`
C03	`09`	`X`	`FRE`	`@0 Atteignabilité @5 12`
C03	`09`	`X`	`ENG`	`@0 Reachability @5 12`
C03	`09`	`X`	`SPA`	`@0 Asequibilidad @5 12`
C03	`10`	`X`	`FRE`	`@0 Cinématique @5 13`
C03	`10`	`X`	`ENG`	`@0 Kinematics @5 13`
C03	`10`	`X`	`SPA`	`@0 Cinemática @5 13`
C03	`11`	`X`	`FRE`	`@0 Traitement associé @5 17`
C03	`11`	`X`	`ENG`	`@0 Combined treatment @5 17`
C03	`11`	`X`	`SPA`	`@0 Tratamiento asociado @5 17`
C03	`12`	`X`	`FRE`	`@0 Pronostic @5 18`
C03	`12`	`X`	`ENG`	`@0 Prognosis @5 18`
C03	`12`	`X`	`SPA`	`@0 Pronóstico @5 18`
C03	`13`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`13`	`X`	`ENG`	`@0 Adult @5 20`
C03	`13`	`X`	`SPA`	`@0 Adulto @5 20`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`03`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`05`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`06`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`06`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`06`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`07`	`X`	`FRE`	`@0 Antiparkinsonien @5 45`
C07	`07`	`X`	`ENG`	`@0 Antiparkinson agent @5 45`
C07	`07`	`X`	`SPA`	`@0 Antiparkinsoniano @5 45`
C07	`08`	`X`	`FRE`	`@0 Chirurgie @5 53`
C07	`08`	`X`	`ENG`	`@0 Surgery @5 53`
C07	`08`	`X`	`SPA`	`@0 Cirugía @5 53`
N21				`@1 033`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 04-0052798 INIST
ET :	Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease
AU :	BASTIAN (Amy J.); KELLY (Valerie E.); PERLMUTTER (Joel S.); MINK (Jonathan W.)
AF :	Kennedy Krieger Institute/Baltimore, Maryland/Etats-Unis (1 aut.); Program in Physical Therapy, Washington University/St. Louis, Missouri/Etats-Unis (1 aut., 2 aut.); Departments of Neurology, Radiology, and Anatomy & Neurobiology, Washington University/St. Louis, Missouri/Etats-Unis (3 aut.); Departments of Neurology (Child Neurology), Neurobiology & Anatomy, and Pediatrics, University of Rochester/Rochester, New York/Etats-Unis (4 aut.); Department of Neurology, Johns Hopkins/Baltimore, Maryland/Etats-Unis
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 9; Pp. 1008-1017; Bibl. 40 ref.
LA :	Anglais
EA :	We examined the effects of levodopa and unilateral pallidotomy on quantitative measures of walking and reaching in Parkinson's disease (PD). We also compared quantitative measures of movement with standard clinical rating scales. We used kinematic measures and the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale (subscale III) to evaluate the movement of 10 people with PD. Subjects were tested after withholding PD medications for at least 8 hours and again 30 to 45 minutes after taking the first morning dose of levodopa. They were studied in this manner before unilateral pallidotomy and then 3.5 to 10 months after surgery. The UPDRS motor subscale was performed in each state. Kinematic data were collected as subjects reached to a target and walked. The UPDRS motor subscale ratings were similar to those reported in the literature: pallidotomy improved the overall motor score and the contralateral bradykinesia + rigidity score, but not the gait + posture score. In contrast, kinematic measures demonstrated that levodopa and pallidotomy had different effects on walking and reaching speed. Both treatments improved walking speed, and the effect was additive. Levodopa improved reaching speed before pallidotomy but did not improve it as much after pallidotomy. Additionally, pallidotomy had inconsistent effects on reaching; some subjects were faster and others were slower. The subjects who initially reached more slowly improved after pallidotomy; the subjects who initially reached more normally (faster) worsened after pallidotomy. On the basis of our results, we speculate that basal ganglia output pathways that control walking and reaching may be distinct. such that bilateral projections to the pedunculopontine area influence walking, whereas ipsilateral thalamocortical projections influence reaching.
CC :	002B02B06; 002B25J01
FD :	Parkinson maladie; Lévodopa; Chimiothérapie; Pallidum; Exérèse; Unilatéral; Marche à pied; Mouvement corporel; Atteignabilité; Cinématique; Traitement associé; Pronostic; Adulte
FG :	Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Antiparkinsonien; Chirurgie
ED :	Parkinson disease; Levodopa; Chemotherapy; Pallidum; Exeresis; Unilateral; Walking; Body movement; Reachability; Kinematics; Combined treatment; Prognosis; Adult
EG :	Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Antiparkinson agent; Surgery
SD :	Parkinson enfermedad; Levodopa; Quimioterapia; Pallidum; Exéresis; Unilateral; Caminata; Movimiento corporal; Asequibilidad; Cinemática; Tratamiento asociado; Pronóstico; Adulto
LO :	INIST-20953.354000113072050060
ID :	04-0052798

Links to Exploration step

Pascal:04-0052798

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease</title>
<author><name sortKey="Bastian, Amy J" sort="Bastian, Amy J" uniqKey="Bastian A" first="Amy J." last="Bastian">Amy J. Bastian</name>
<affiliation><inist:fA14 i1="01"><s1>Kennedy Krieger Institute</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Program in Physical Therapy, Washington University</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Johns Hopkins</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kelly, Valerie E" sort="Kelly, Valerie E" uniqKey="Kelly V" first="Valerie E." last="Kelly">Valerie E. Kelly</name>
<affiliation><inist:fA14 i1="02"><s1>Program in Physical Therapy, Washington University</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Neurology, Radiology, and Anatomy & Neurobiology, Washington University</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name>
<affiliation><inist:fA14 i1="04"><s1>Departments of Neurology (Child Neurology), Neurobiology & Anatomy, and Pediatrics, University of Rochester</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0052798</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0052798 INIST</idno>
<idno type="RBID">Pascal:04-0052798</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002394</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease</title>
<author><name sortKey="Bastian, Amy J" sort="Bastian, Amy J" uniqKey="Bastian A" first="Amy J." last="Bastian">Amy J. Bastian</name>
<affiliation><inist:fA14 i1="01"><s1>Kennedy Krieger Institute</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Program in Physical Therapy, Washington University</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Department of Neurology, Johns Hopkins</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kelly, Valerie E" sort="Kelly, Valerie E" uniqKey="Kelly V" first="Valerie E." last="Kelly">Valerie E. Kelly</name>
<affiliation><inist:fA14 i1="02"><s1>Program in Physical Therapy, Washington University</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Perlmutter, Joel S" sort="Perlmutter, Joel S" uniqKey="Perlmutter J" first="Joel S." last="Perlmutter">Joel S. Perlmutter</name>
<affiliation><inist:fA14 i1="03"><s1>Departments of Neurology, Radiology, and Anatomy & Neurobiology, Washington University</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mink, Jonathan W" sort="Mink, Jonathan W" uniqKey="Mink J" first="Jonathan W." last="Mink">Jonathan W. Mink</name>
<affiliation><inist:fA14 i1="04"><s1>Departments of Neurology (Child Neurology), Neurobiology & Anatomy, and Pediatrics, University of Rochester</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Body movement</term>
<term>Chemotherapy</term>
<term>Combined treatment</term>
<term>Exeresis</term>
<term>Kinematics</term>
<term>Levodopa</term>
<term>Pallidum</term>
<term>Parkinson disease</term>
<term>Prognosis</term>
<term>Reachability</term>
<term>Unilateral</term>
<term>Walking</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Pallidum</term>
<term>Exérèse</term>
<term>Unilatéral</term>
<term>Marche à pied</term>
<term>Mouvement corporel</term>
<term>Atteignabilité</term>
<term>Cinématique</term>
<term>Traitement associé</term>
<term>Pronostic</term>
<term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We examined the effects of levodopa and unilateral pallidotomy on quantitative measures of walking and reaching in Parkinson's disease (PD). We also compared quantitative measures of movement with standard clinical rating scales. We used kinematic measures and the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale (subscale III) to evaluate the movement of 10 people with PD. Subjects were tested after withholding PD medications for at least 8 hours and again 30 to 45 minutes after taking the first morning dose of levodopa. They were studied in this manner before unilateral pallidotomy and then 3.5 to 10 months after surgery. The UPDRS motor subscale was performed in each state. Kinematic data were collected as subjects reached to a target and walked. The UPDRS motor subscale ratings were similar to those reported in the literature: pallidotomy improved the overall motor score and the contralateral bradykinesia + rigidity score, but not the gait + posture score. In contrast, kinematic measures demonstrated that levodopa and pallidotomy had different effects on walking and reaching speed. Both treatments improved walking speed, and the effect was additive. Levodopa improved reaching speed before pallidotomy but did not improve it as much after pallidotomy. Additionally, pallidotomy had inconsistent effects on reaching; some subjects were faster and others were slower. The subjects who initially reached more slowly improved after pallidotomy; the subjects who initially reached more normally (faster) worsened after pallidotomy. On the basis of our results, we speculate that basal ganglia output pathways that control walking and reaching may be distinct. such that bilateral projections to the pedunculopontine area influence walking, whereas ipsilateral thalamocortical projections influence reaching.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>9</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BASTIAN (Amy J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KELLY (Valerie E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PERLMUTTER (Joel S.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>MINK (Jonathan W.)</s1>
</fA11>
<fA14 i1="01"><s1>Kennedy Krieger Institute</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Program in Physical Therapy, Washington University</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Departments of Neurology, Radiology, and Anatomy & Neurobiology, Washington University</s1>
<s2>St. Louis, Missouri</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Departments of Neurology (Child Neurology), Neurobiology & Anatomy, and Pediatrics, University of Rochester</s1>
<s2>Rochester, New York</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Johns Hopkins</s1>
<s2>Baltimore, Maryland</s2>
<s3>USA</s3>
</fA14>
<fA20><s1>1008-1017</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113072050060</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>40 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0052798</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We examined the effects of levodopa and unilateral pallidotomy on quantitative measures of walking and reaching in Parkinson's disease (PD). We also compared quantitative measures of movement with standard clinical rating scales. We used kinematic measures and the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale (subscale III) to evaluate the movement of 10 people with PD. Subjects were tested after withholding PD medications for at least 8 hours and again 30 to 45 minutes after taking the first morning dose of levodopa. They were studied in this manner before unilateral pallidotomy and then 3.5 to 10 months after surgery. The UPDRS motor subscale was performed in each state. Kinematic data were collected as subjects reached to a target and walked. The UPDRS motor subscale ratings were similar to those reported in the literature: pallidotomy improved the overall motor score and the contralateral bradykinesia + rigidity score, but not the gait + posture score. In contrast, kinematic measures demonstrated that levodopa and pallidotomy had different effects on walking and reaching speed. Both treatments improved walking speed, and the effect was additive. Levodopa improved reaching speed before pallidotomy but did not improve it as much after pallidotomy. Additionally, pallidotomy had inconsistent effects on reaching; some subjects were faster and others were slower. The subjects who initially reached more slowly improved after pallidotomy; the subjects who initially reached more normally (faster) worsened after pallidotomy. On the basis of our results, we speculate that basal ganglia output pathways that control walking and reaching may be distinct. such that bilateral projections to the pedunculopontine area influence walking, whereas ipsilateral thalamocortical projections influence reaching.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B25J01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pallidum</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Pallidum</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Pallidum</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Exérèse</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Exeresis</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Exéresis</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Unilatéral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Unilateral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Unilateral</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Marche à pied</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Walking</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Caminata</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Mouvement corporel</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Body movement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Movimiento corporal</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Atteignabilité</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Reachability</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Asequibilidad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Cinématique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Kinematics</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Cinemática</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Traitement associé</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Combined treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Tratamiento asociado</s0>
<s5>17</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>18</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Surgery</s0>
<s5>53</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>53</s5>
</fC07>
<fN21><s1>033</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 04-0052798 INIST</NO>
<ET>Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease</ET>
<AU>BASTIAN (Amy J.); KELLY (Valerie E.); PERLMUTTER (Joel S.); MINK (Jonathan W.)</AU>
<AF>Kennedy Krieger Institute/Baltimore, Maryland/Etats-Unis (1 aut.); Program in Physical Therapy, Washington University/St. Louis, Missouri/Etats-Unis (1 aut., 2 aut.); Departments of Neurology, Radiology, and Anatomy & Neurobiology, Washington University/St. Louis, Missouri/Etats-Unis (3 aut.); Departments of Neurology (Child Neurology), Neurobiology & Anatomy, and Pediatrics, University of Rochester/Rochester, New York/Etats-Unis (4 aut.); Department of Neurology, Johns Hopkins/Baltimore, Maryland/Etats-Unis</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2003; Vol. 18; No. 9; Pp. 1008-1017; Bibl. 40 ref.</SO>
<LA>Anglais</LA>
<EA>We examined the effects of levodopa and unilateral pallidotomy on quantitative measures of walking and reaching in Parkinson's disease (PD). We also compared quantitative measures of movement with standard clinical rating scales. We used kinematic measures and the Unified Parkinson's Disease Rating Scale (UPDRS) motor subscale (subscale III) to evaluate the movement of 10 people with PD. Subjects were tested after withholding PD medications for at least 8 hours and again 30 to 45 minutes after taking the first morning dose of levodopa. They were studied in this manner before unilateral pallidotomy and then 3.5 to 10 months after surgery. The UPDRS motor subscale was performed in each state. Kinematic data were collected as subjects reached to a target and walked. The UPDRS motor subscale ratings were similar to those reported in the literature: pallidotomy improved the overall motor score and the contralateral bradykinesia + rigidity score, but not the gait + posture score. In contrast, kinematic measures demonstrated that levodopa and pallidotomy had different effects on walking and reaching speed. Both treatments improved walking speed, and the effect was additive. Levodopa improved reaching speed before pallidotomy but did not improve it as much after pallidotomy. Additionally, pallidotomy had inconsistent effects on reaching; some subjects were faster and others were slower. The subjects who initially reached more slowly improved after pallidotomy; the subjects who initially reached more normally (faster) worsened after pallidotomy. On the basis of our results, we speculate that basal ganglia output pathways that control walking and reaching may be distinct. such that bilateral projections to the pedunculopontine area influence walking, whereas ipsilateral thalamocortical projections influence reaching.</EA>
<CC>002B02B06; 002B25J01</CC>
<FD>Parkinson maladie; Lévodopa; Chimiothérapie; Pallidum; Exérèse; Unilatéral; Marche à pied; Mouvement corporel; Atteignabilité; Cinématique; Traitement associé; Pronostic; Adulte</FD>
<FG>Homme; Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Antiparkinsonien; Chirurgie</FG>
<ED>Parkinson disease; Levodopa; Chemotherapy; Pallidum; Exeresis; Unilateral; Walking; Body movement; Reachability; Kinematics; Combined treatment; Prognosis; Adult</ED>
<EG>Human; Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Antiparkinson agent; Surgery</EG>
<SD>Parkinson enfermedad; Levodopa; Quimioterapia; Pallidum; Exéresis; Unilateral; Caminata; Movimiento corporal; Asequibilidad; Cinemática; Tratamiento asociado; Pronóstico; Adulto</SD>
<LO>INIST-20953.354000113072050060</LO>
<ID>04-0052798</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002394 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002394 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:04-0052798
   |texte=   Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease

Effects of pallidotomy and levodopa on walking and reaching movements in Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri